Literature DB >> 23523954

Concurrent targeting of eicosanoid receptor 1/eicosanoid receptor 4 receptors and COX-2 induces synergistic apoptosis in Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus associated non-Hodgkin lymphoma cell lines.

Arun George Paul1, Bala Chandran, Neelam Sharma-Walia.   

Abstract

The effective antitumorigenic potential of nonsteroidal anti-inflammatory drugs (NSAIDs) and eicosonoid (EP; EP1-4) receptor antagonists prompted us to test their efficacy in Kaposi's sarcoma-associated herpesvirus (KSHV) and Epstein-Barr virus (EBV) related lymphomas. Our study demonstrated that (1) EP1-4 receptor protein levels vary among the various non-Hodgkin's lymphoma (NHL) cell lines tested (BCBL-1:KSHV+/EBV-;BC-3: KSHV+/EBV-; Akata/EBV+: KSHV-/EBV+; and JSC-1 cells: KSHV+/EBV + cells); (2) 5.0 μM of EP1 antagonist (SC-51322) had a significant antiproliferative effect on BCBL-1, BC-3, Akata/EBV+, and JSC-1 cells; (3) 50.0 μM of EP2 antagonist (AH6809) was required to induce a significant antiproliferative effect on BCBL-1, Akata/EBV+, and JSC-1 cells; (4) 5.0 μM of EP4 antagonist (GW 627368X) had a significant antiproliferative effect on BC-3, Akata/EBV+, and JSC-1 cells; (5) COX-2 selective inhibitor celecoxib (5.0 μM) had significant antiproliferative effects on BCBL-1, BC-3, Akata/EBV+, and JSC-1 cells; and (6) a combination of 1.0 μM each of celecoxib, SC-51322 and GW 627368X could potentiate the proapoptotic properties of celecoxib or vice-versa. Overall, our studies identified the synergistic antiproliferative effect of NSAIDs and EP receptor blockers on KSHV and EBV related B cell malignancies.
Copyright © 2013 Mosby, Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23523954      PMCID： PMC4672642          DOI： 10.1016/j.trsl.2013.02.008

Source DB:  PubMed          Journal:  Transl Res        ISSN： 1878-1810            Impact factor:   7.012


  121 in total

1.  Role of the Kaposi's sarcoma-associated herpesvirus K15 SH3 binding site in inflammatory signaling and B-cell activation.

Authors:  Marcel Pietrek; Melanie M Brinkmann; Ilona Glowacka; Anette Enlund; Anika Hävemeier; Oliver Dittrich-Breiholz; Michael Kracht; Marc Lewitzky; Kalle Saksela; Stephan M Feller; Thomas F Schulz
Journal:  J Virol       Date:  2010-06-09       Impact factor: 5.103

2.  Dimethyl-celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-inhibitory function, potently mimics the anti-tumor effects of celecoxib on Burkitt's lymphoma in vitro and in vivo.

Authors:  Adel Kardosh; Weijun Wang; Jasim Uddin; Nicos A Petasis; Florence M Hofman; Thomas C Chen; Axel H Schönthal
Journal:  Cancer Biol Ther       Date:  2005-05-05       Impact factor: 4.742

Review 3.  KSHV and Kaposi's sarcoma: the end of the beginning?

Authors:  D Ganem
Journal:  Cell       Date:  1997-10-17       Impact factor: 41.582

Review 4.  DNA damage checkpoints in stem cells, ageing and cancer.

Authors:  Tobias Sperka; Jianwei Wang; K Lenhard Rudolph
Journal:  Nat Rev Mol Cell Biol       Date:  2012-09       Impact factor: 94.444

Review 5.  Targeting human herpesvirus-8 for treatment of Kaposi's sarcoma and primary effusion lymphoma.

Authors:  Carmen Manuela Klass; Margaret K Offermann
Journal:  Curr Opin Oncol       Date:  2005-09       Impact factor: 3.645

6.  The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation.

Authors:  T J Seng; J S W Low; H Li; Y Cui; H K Goh; M L Y Wong; G Srivastava; D Sidransky; J Califano; R D M Steenbergen; S Y Rha; J Tan; W-S Hsieh; R F Ambinder; X Lin; A T C Chan; Q Tao
Journal:  Oncogene       Date:  2006-07-24       Impact factor: 9.867

Review 7.  Profiling aberrant DNA methylation in hematologic neoplasms: a view from the tip of the iceberg.

Authors:  Manel Esteller
Journal:  Clin Immunol       Date:  2003-10       Impact factor: 3.969

8.  Prostaglandin E2 receptors and COX enzymes in human hepatocellular carcinoma: role in the regulation of cell growth.

Authors:  Antonella Cusimano; Daniela Foderà; Nadia Lampiasi; Antonina Azzolina; Monica Notarbartolo; Lydia Giannitrapani; Natale D'Alessandro; Giuseppe Montalto; Melchiorre Cervello
Journal:  Ann N Y Acad Sci       Date:  2009-02       Impact factor: 5.691

9.  Targeting KSHV/HHV-8 latency with COX-2 selective inhibitor nimesulide: a potential chemotherapeutic modality for primary effusion lymphoma.

Authors:  Arun George Paul; Neelam Sharma-Walia; Bala Chandran
Journal:  PLoS One       Date:  2011-09-30       Impact factor: 3.240

10.  Suppressive regulation of KSHV RTA with O-GlcNAcylation.

Authors:  Ying-Chieh Ko; Wan-Hua Tsai; Pei-Wen Wang; I-Lin Wu; Shu-Yu Lin; Yu-Lian Chen; Jen-Yang Chen; Su-Fang Lin
Journal:  J Biomed Sci       Date:  2012-02-02       Impact factor: 8.410
View more
  13 in total

1.  Activated Nrf2 Interacts with Kaposi's Sarcoma-Associated Herpesvirus Latency Protein LANA-1 and Host Protein KAP1 To Mediate Global Lytic Gene Repression.

Authors:  Olsi Gjyshi; Arunava Roy; Sujoy Dutta; Mohanan Valiya Veettil; Dipanjan Dutta; Bala Chandran
Journal:  J Virol       Date:  2015-05-20       Impact factor: 5.103

Review 2.  Combination of celecoxib (Celebrex®) and CD19 CAR-redirected CTL immunotherapy for the treatment of B-cell non-Hodgkin's lymphomas.

Authors:  Tam Nm Dinh; Alexandra S Onea; Ali R Jazirehi
Journal:  Am J Clin Exp Immunol       Date:  2017-05-15

3.  The Kaposi's sarcoma-associated herpesvirus (KSHV)-induced 5-lipoxygenase-leukotriene B4 cascade plays key roles in KSHV latency, monocyte recruitment, and lipogenesis.

Authors:  Neelam Sharma-Walia; Karthic Chandran; Kinjan Patel; Mohanan Valiya Veettil; Alexandru Marginean
Journal:  J Virol       Date:  2013-12-11       Impact factor: 5.103

4.  Altering the Anti-inflammatory Lipoxin Microenvironment: a New Insight into Kaposi's Sarcoma-Associated Herpesvirus Pathogenesis.

Authors:  Jayashree A Chandrasekharan; Xiao M Huang; Alexander C Hwang; Neelam Sharma-Walia
Journal:  J Virol       Date:  2016-11-28       Impact factor: 5.103

Review 5.  Prostaglandin Pathways: Opportunities for Cancer Prevention and Therapy.

Authors:  Qiushi Wang; Rebecca J Morris; Ann M Bode; Tianshun Zhang
Journal:  Cancer Res       Date:  2022-03-15       Impact factor: 13.312

6.  Celecoxib Inhibits the Lytic Activation of Kaposi's Sarcoma-Associated Herpesvirus through Down-Regulation of RTA Expression by Inhibiting the Activation of p38 MAPK.

Authors:  Jungang Chen; Liangyu Jiang; Ke Lan; Xulin Chen
Journal:  Viruses       Date:  2015-05-05       Impact factor: 5.048

7.  Kaposi's sarcoma-associated herpesvirus induces Nrf2 during de novo infection of endothelial cells to create a microenvironment conducive to infection.

Authors:  Olsi Gjyshi; Virginie Bottero; Mohanan Valliya Veettil; Sujoy Dutta; Vivek Vikram Singh; Leela Chikoti; Bala Chandran
Journal:  PLoS Pathog       Date:  2014-10-23       Impact factor: 6.823

Review 8.  Role of Modulator of Inflammation Cyclooxygenase-2 in Gammaherpesvirus Mediated Tumorigenesis.

Authors:  Jaya Gandhi; Lohit Khera; Nivedita Gaur; Catherine Paul; Rajeev Kaul
Journal:  Front Microbiol       Date:  2017-03-28       Impact factor: 5.640

Review 9.  Virus and tumor microenvironment induced ER stress and unfolded protein response: from complexity to therapeutics.

Authors:  Kumari Asha; Neelam Sharma-Walia
Journal:  Oncotarget       Date:  2018-08-07

Review 10.  Lipoxins: nature's way to resolve inflammation.

Authors:  Jayashree A Chandrasekharan; Neelam Sharma-Walia
Journal:  J Inflamm Res       Date:  2015-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.